RenovoRx financials
$1.57+1.29%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $43.0K | $0.00 | $0.00 | — |
| Gross profit | $796.0K | $43.0K | $0.00 | $0.00 | — |
| Gross margin | 70.9% | 100.0% | — | — | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | -$6.3M |
| Net margin | −994.5% | −20497.7% | — | — | — |
| Diluted EPS | $-0.32 | $-0.40 | $-0.99 | $-1.09 | $-1.21 |
| EBITDA | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M |
| Operating cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M |
| Free cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M |
| Diluted shares | 35.3M | 22.3M | 10.3M | 9.1M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.0M | $7.2M | $1.2M | $4.4M | $15.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $2.0M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938.0K |
| Shareholders' equity | $5.4M | $4.5M | -$3.0M | $6.2M | $15.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology